| Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share |
The following potentially dilutive outstanding securities were excluded from diluted EPS for the period indicated because of their anti-dilutive effect: | | | | | | | | | | | | | | | | | | | | | | | | | Potentially dilutive securities | Three Months Ended
June 30, | | Six Months Ended
June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Stock options | 1,875,910 | | | 1,121,802 | | | 1,875,910 | | | 1,121,802 | | Common stock warrants | 1,940,371 | | | 1,268,572 | | | 1,940,371 | | | 1,268,572 | | | Common stock issuable upon settlement of restricted stock units | 145,969 | | | — | | | 145,969 | | | — | | Common stock issuable upon conversion of Series A Preferred Stock | 151,800 | | | — | | | 151,800 | | | — | | Common stock issuable upon exercise or conversion of the securities underlying the Agent Units | 40,300 | | | — | | | 40,300 | | | — | | | Total | 4,154,350 | | | 2,390,374 | | | 4,154,350 | | | 2,390,374 | |
|